Related Experiment Video
Updated: Aug 13, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Current and emerging second-generation triptans in acute migraine therapy: a comparative review
1Department of Clinical Pharmacology, College of Medicine, Sultan Qaboos University Hospital, Sultanate of Oman.
Journal of Clinical Pharmacology
|July 7, 2000
Summary
Second-generation triptans offer new options for migraine treatment by targeting neurogenic inflammation. This review compares their efficacy and safety against sumatriptan.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Migraine pathophysiology involves sterile neurogenic inflammation in cephalic tissues.
- 5-hydroxytryptamine (5-HT1B/1D) agonists, known as triptans, inhibit this inflammation by acting on specific receptors.
Purpose of the Study:
- To review and compare second-generation 5-HT1B/1D agonists for acute migraine treatment.
- Evaluate their pharmacological properties, pharmacokinetics, clinical efficacy, and safety profiles.
Main Methods:
- In vitro pharmacological property assessment.
- Pharmacokinetic analysis.
- Clinical efficacy and adverse effect evaluation.
- Comparison with sumatriptan.
Main Results:
- Second-generation triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan) exhibit distinct in vitro and pharmacokinetic profiles.
- Clinical data suggests varying efficacy and tolerability among these agents.
- Adverse effect profiles are detailed and compared to sumatriptan.
Conclusions:
- Second-generation triptans represent advancements in acute migraine therapy.
- Individual agent selection may depend on patient-specific factors and treatment goals.
- Further comparative studies are valuable for optimizing migraine management.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...